Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
Location: China, Hong Kong, Sha Tin District
Investors 1
| Date | Name | Website |
| 21.08.2023 | Gobi Partn... | gobi.vc |
Mentions in press and media 14
| Date | Title | Description |
| 06.10.2025 | Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition | “a prominent recognition attracting RMB 60M investment EOI” HONG KONG SAR – Media OutReach Newswire – 6 October 2025 – Immuno Cure BioTech (“Immuno Cure“) is delighted to announce victory at the National Final of the 1st GBA Entrepreneurshi... |
| 30.07.2025 | Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone | “Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project” HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Great... |
| 19.06.2025 | Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans | HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the ... |
| 13.11.2024 | FinTech and Biotech: A Tale of Innovation and Hope | In the bustling corridors of innovation, two stories emerge from Asia, each a beacon of progress in its field. On one side, we have On-us, a FinTech player redefining digital incentives. On the other, Immuno Cure Biotech, a pioneer in the f... |
| 12.11.2024 | Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine | Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Immuno Cure BioTech (“Immuno Cure“), a c... |
| 17.07.2024 | HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council | Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions HONG KONG SAR – Media OutReach Newswire – 18 July 2024 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today that a collaborative researc... |
| 03.06.2024 | Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding | HONG KONG SAR – Media OutReach Newswire – 3 June 2024 – Immuno Cure BioTech (“Immuno Cure“) is delighted to announce that our pipeline product “Anti-Δ42PD1 Antibody against hepatocellular carcinoma (HCC)”, sublicensed to Orimmune BioTech Li... |
| 04.08.2023 | Gobi Partners’ strategic health tech investments signal growth opportunities in Asia | To solidify its position in the health tech sector, pan-Asian venture capital firm Gobi Partners has announced simultaneous investments in two key regions: China’s Greater Bay Area and Southeast Asia. With a total investment of USD 11.8 mil... |
| 27.07.2023 | Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA | Advancing DNA vaccines & Immunotherapies for HIV, Cancers & Infectious Diseases HONG KONG SAR – Media OutReach – 27 July 2023 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today that it has closed the US$12 million tr... |
| 26.07.2023 | HK biotech firm Immuno Cure gears up for IPO with $12m funding | InvestmentsNewsStartups Lokesh Choudhary · 27 Jul 2023 · 2 min readHK biotech firm Immuno Cure gears up for IPO with $12m funding Photo credit: Shutterstock Immuno Cure has raised US$12 million as part of its US$27 million series A round. T... |
Show more